Boehringer Ingelheim and Sanofi Join the CATALIS Network

New pharmaceutical industry partners are supporting CATALIS in making Quebec a world leader in clinical research.

MONTREAL, May 20, 2021 —CATALIS Québec is proud to announce that two pharmaceutical companies, Boehringer Ingelheim and Sanofi, have joined its network of partners who are working together to support Quebec’s competitiveness in conducting clinical trials.

In February 2021, the Ministry of Economy and Innovation (MEI) provided CATALIS Québec with $15 million in financing to coordinate a large network of public-private partners whose objective is to support implementation of concrete and sustainable solutions that will position Quebec among the world leaders in clinical research. CATALIS Québec’s strategic objectives are to accelerate the launch and optimize the conduct of clinical trials in Quebec, facilitate patient recruitment, and increase Quebec’s international exposure in order to attract more privately-financed clinical trials

“We are very pleased to welcome Boehringer Ingelheim and Sanofi to our network, which includes some of Quebec’s health and social services institutions network, world-renowned pharmaceutical companies, and other clinical research organizations. These new partners will actively contribute to the development of the new Quebec clinical trial acceleration program, which aims to accelerate the research for innovative treatments for patients,” stated Danika Laberge, General Manager of CATALIS Québec.

Boehringer Ingelheim is an international pharmaceutical company that creates value through innovation and the research and development of innovative therapeutic products. “We are a company deeply committed to the mission of turning focused innovations into life-changing treatments for patients. At Boehringer Ingelheim, we appreciate the value and potential the partnership with Quebec-based, CATALIS brings. We believe the integration of key stakeholders, in research activities will benefit our research centers, industry partners, and most importantly our patients.” Gabriel Kim, VP Medical and Regulatory

Sanofi has two facilities in Quebec and is actively involved in researching new innovative treatments. “As an industry innovation leader bringing transformative solutions to patients, we are excited to partner with CATALIS in optimizing the clinical research environment, attracting more clinical trials to Quebec as we strive to deliver innovative therapies to patients sooner”, stated Mary Tzortzis, Country Head, Clinical Study Unit.


About CATALIS Québec

CATALIS is a not-for-profit organization whose objective is to promote Quebec’s development and operational excellence in clinical research. Our mission is to optimize Quebec’s clinical research environment in order to maximize private investment and accelerate the development of innovative patient care. Our vision is to create an environment in which all patients can easily access clinical trials in Quebec. More information is available at

About Boehringer Ingelheim (Canada) Ltd. 

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Approximately 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada. Learn more at

About Sanofi Canada

Sanofi Canada advances healthcare for the whole person and every person. A leading investor in life sciences, manufacturing and research and development, the company creates life changing and lifesaving products grounded in science that Canadians can trust. Sanofi empowers self-care, prevents and treats disease and helps people living with illnesses live better.